| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004356 | American Journal of Ophthalmology | 2009 | 9 Pages |
Abstract
High-dose intravenous daclizumab can help reduce active inflammation in active JIA-associated anterior uveitis; however, patients need to be monitored for potential side effects. Larger randomized trials are needed to better assess treatment effect and safety.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
H. Nida Sen, Grace Levy-Clarke, Lisa J. Faia, Zhuqing Li, Steven Yeh, Karyl S. Barron, John G. Ryan, Keri Hammel, Robert B. Nussenblatt,